title: Effect of the long-acting somatostatin analogue SMS 201-995 on growth rate and reduction of predicted adult height in ten tall adolescents.
abstract: Ten adolescents (four boys and six girls) aged 11.5 to 17 years, presenting with constitutionally tall stature were treated with twice daily subcutaneous injections of 250 micrograms of SMS 201-995 (Sandostatin). Results are reported after 6 and 12 months of therapy. Reduction of growth rate was obtained in 9 patients and correlated with the reduction of 24-hour growth hormone pulsatility and with the decrease of plasma Somatomedin-C values. Moreover, acceleration of bone maturation on SMS 201-995 therapy occurred in seven patients, and mean bone age increased from 13.3 years to 14.5 and 15.8 years after 6 and 12 months of SMS therapy. The mean reduction of predicted adult height was 4.9 cm at the last evaluation after 6 or 12 months of therapy. The dual effect of SMS 201-995 on growth rate and bone maturation suggests that it may be an alternative treatment to reduce adult height.
authors.affiliation: Department of Paediatrics, Centre Hospitalier Universitaire de Rangueil, Toulouse, France.
authors.forename: M T
authors.initials: MT
authors.lastname: Tauber
authors.forename: J P
authors.initials: JP
authors.lastname: Tauber
authors.forename: F
authors.initials: F
authors.lastname: Vigoni
authors.forename: A G
authors.initials: AG
authors.lastname: Harris
authors.forename: P
authors.initials: P
authors.lastname: Rochicchioli
mesh_terms: D000293:Adolescent; D000365:Age Determination by Skeleton; D001827:Body Height / Q000187:drug effects*; D002648:Child; D003864:Depression, Chemical; D004361:Drug Tolerance; D005260:Female; D006128:Growth / Q000187:drug effects*; D006130:Growth Disorders / Q000188:drug therapy; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D015282:Octreotide / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D007334:Insulin-Like Growth Factor I; D015282:Octreotide